XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLO

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/19	21 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/12/19	21 : 30	GlobeNewswire Inc.	Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI	NASDAQ:XLO	Xilio Therapeutics Inc
2024/12/16	21 : 30	GlobeNewswire Inc.	Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer	NASDAQ:XLO	Xilio Therapeutics Inc
2024/12/04	06 : 30	GlobeNewswire Inc.	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:XLO	Xilio Therapeutics Inc
2024/11/07	23 : 25	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XLO	Xilio Therapeutics Inc
2024/11/07	23 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/11/07	23 : 15	GlobeNewswire Inc.	Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors	NASDAQ:XLO	Xilio Therapeutics Inc
2024/11/07	23 : 05	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
2024/10/30	22 : 01	GlobeNewswire Inc.	Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
2024/10/04	22 : 05	GlobeNewswire Inc.	Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
2024/10/03	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/10/03	05 : 15	GlobeNewswire Inc.	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 36	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 36	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 36	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 36	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/28	10 : 00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/09/14	05 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/08/29	05 : 01	GlobeNewswire Inc.	Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference	NASDAQ:XLO	Xilio Therapeutics Inc
2024/08/08	20 : 51	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XLO	Xilio Therapeutics Inc
2024/08/08	20 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/08/08	20 : 30	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
2024/08/07	09 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/06/18	05 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/06/18	05 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/06/18	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/06/14	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc